Refine your search:     
Report No.

Production and utilization of new radioisotopes for theraputic and diagnostic applications in cancer

Iida, Yasuhiko*; Hanaoka, Hirofumi*; Yoshioka, Hiroki*; Takayanagi, Megumi*; Watanabe, Shigeki; Ishioka, Noriko; Watanabe, Satoshi; Matsuhashi, Shimpei; Paudyal, P.*; Higuchi, Tetsuya*; Oriuchi, Noboru*; Endo, Keigo*

Some new radionuclides would be useful for cancer diagnosis and therapy. Our project is to prepare these radionuclides, to apply them to many radiopharmaceuticals and to investigate usefullness of those new radiopharmaceuticals. Radio immuno therapy (RIT) is one of the most promising treatments for cancer therapy. And assessment of radiation dose to both tumor and normal tissues is very important to RIT. PET can estimate radiation dose directly, but general positron emittors don't suit for labeling of antibody because of their short half-lives. $$^{64}$$Cu and $$^{76}$$Br have appropriate properties ($$^{64}$$Cu: T$$_{1/2}$$ = 12.7 hr, $$^{76}$$Br: T$$_{1/2}$$ = 16.1 hr) and they may have great potentials for immuno-PET. We have synthesized $$^{64}$$Cu or $$^{76}$$Br labeled monoclonal antibody and evaluated potentials for in vivo quantitative evaluation of RIT. And we synthesized $$^{76}$$Br labeled glucose ($$^{76}$$BrDG). We evaluated its utility for tumor diagnosis. These new radiopharmaceuticals are very useful for cancer diagnosis and therapy. We will develop various radiopharmaceuticals labeled with these new radionuclides and apply them to clinical medicine in future.



- Accesses





[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.